150 withdrawn. 150 Phase 2, 44 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 150 | Withdrawn 150 |
| Phase 1 | 44 | Withdrawn 44 |
| Phase 3 | 3 | Withdrawn 3 |
Follow Neoplasms, Nerve Tissue: new trials by email Literature Review of Neoplasms, Nerve Tissue trials Research Report on Neoplasms, Nerve Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ONC201 for Refractory Meningioma ONC201 - Meningioma, Refractory Meningioma | Phase 2 | Withdrawn | University of Nebraska | 2026-12-01 | 2026-01-26 | |
| Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma Ipilimumab, Nivolumab - Melanoma | Phase 2 | Withdrawn | University of Utah | 2026-10-01 | 2026-10-19 | |
| Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma Biospecimen Collection, Computed Tomography, Florbenguane F18 - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 2 | Withdrawn | Children's Oncology Group | 2026-09-22 | 2026-09-16 | |
| Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC Ga-68- DOTATATE, Ga-68-DOTATOC - Meningioma | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2026-08-01 | 2026-08-31 | |
| EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis Methoxsalen, Infliximab, Vedolizumab - Immune-related Colitis | Phase 2 | Withdrawn | Therakos LLC | 2025-12-15 | 2025-12-26 | |
| NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis NovoTTF-200A, Pembrolizumab - Metastatic Melanoma, Melanoma Brain Metastasis | Phase 1 / Phase 2 | Withdrawn | Brown University | 2025-10-30 | 2026-01-02 | |
| HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Biological G207 - Neoplasms, High Grade Glioma | Phase 2 | Withdrawn | Pediatric Brain Tumor Consortium | 2025-09-01 | 2026-02-10 | |
| Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma Iron dextran 1000 mg IV - Anemia, Iron Deficiency, Melanoma | Phase 2 | Withdrawn | Indiana University | 2025-05-01 | 2025-07-09 | |
| Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma Atezolizumab, Biospecimen Collection, Magnetic Resonance Imaging - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-04-30 | 2024-12-30 | |
| 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System 18F-mFBG - Neuroblastoma, Pheochromocytoma | Phase 2 | Withdrawn | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 2025-01-01 | 2025-01-21 | |
| A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma Rivoceranib - Metastatic Olfactory Neuroblastoma, Recurrent Olfactory Neuroblastoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-11-01 | 2025-01-10 | |
| Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Defibrotide - Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma | Phase 2 | Withdrawn | University of California, San Francisco | 2024-08-01 | 2024-08-07 | |
| Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab - Recurrent Glioblastoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-07-30 | 2024-11-20 | |
| A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma ONC201 - Glioblastoma | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2024-06-28 | 2023-11-24 | |
| A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients ONCOS-102, Balstilimab - Melanoma | Phase 2 | Withdrawn | Targovax Oy | 2024-01-01 | 2023-06-22 | |
| The Addition of Chloroquine to Chemoradiation for Glioblastoma, Chloroquine - Glioblastoma, Astrocytoma, Grade IV | Phase 2 | Withdrawn | Maastricht Radiation Oncology | 2023-11-10 | 2023-11-18 | |
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, Phaseâ…¡, Double-Blinded, Placebo-Controlled Study Selumetinib, Placebo - Neurofibromatosis Type 1, Plexiform Neurofibromas | Phase 2 | Withdrawn | AstraZeneca | 2023-08-31 | 2023-08-14 | |
| GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients GR-MD-02, Placebo, Pembrolizumab - Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Providence Health & Services | 2023-07-01 | 2023-06-06 | |
| A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer Nivolumab/rHuPH20, Nivolumab - Melanoma, Urothelial Carcinoma | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2023-05-31 | 2023-04-14 | |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Milademetan, Atezolizumab - Advanced Solid Tumor, CDKN2A | Phase 1 / Phase 2 | Withdrawn | Rain Oncology Inc | 2023-05-19 | 2023-10-19 |
Showing 20 of 150. Sign in to see all of them.
Melanoma (61) · Glioblastoma (36) · Glioma (23) · Brain Neoplasms (12) · Neuroblastoma (11) · Gliosarcoma (9) · Neuroendocrine Tumors (9) · Recurrence (9) · Oligodendroglioma (8) · Astrocytoma (7) · Central Nervous System Neoplasms (7) · Neoplasm Metastasis (6) · Neoplasms (6) · Carcinoma, Merkel Cell (5) · Carcinoma, Renal Cell (5)
Neoplasms by Histologic Type (150) · Neoplasms (144) · Neoplasms, Germ Cell and Embryonal (142) · Neuroectodermal Tumors (142) · Neoplasms by Site (92) · Neoplasms, Glandular and Epithelial (82) · Neuroendocrine Tumors (75) · Nevi and Melanomas (64) · Skin Diseases (63) · Skin and Connective Tissue Diseases (63) · Neoplasms, Neuroepithelial (61) · Skin Neoplasms (58) · Astrocytoma (29) · Nervous System Diseases (29)
Nivolumab (14) · Ipilimumab (13) · pembrolizumab (12) · Temozolomide (8) · Bevacizumab (7) · Magnetic Resonance Spectroscopy (7) · Radiotherapy (7) · Interleukin-2 (5) · trametinib (5) · 130-nm albumin-bound paclitaxel (4) · Cyclophosphamide (4) · Radiation (4) · 3-Iodobenzylguanidine (3) · Carboplatin (3) · Carmustine (3)
M.D. Anderson Cancer Center (9) · National Cancer Institute (NCI) (8) · Dana-Farber Cancer Institute (5) · Bristol-Myers Squibb (4) · Jonsson Comprehensive Cancer Center (4) · NYU Langone Health (4) · Duke University (3) · Fuda Cancer Hospital, Guangzhou (3) · Masonic Cancer Center, University of Minnesota (3) · University of Texas Southwestern Medical Center (3) · Children's Oncology Group (2) · Hadassah Medical Organization (2) · ImmunityBio, Inc. (2) · Indiana University (2) · Providence Health & Services (2)
United States (71) · Germany (4) · Spain (4) · Australia (3) · Canada (3) · China (3) · France (3) · Italy (3) · Brazil (2) · Netherlands (2) · Russia (2) · Sweden (2) · Switzerland (2) · United Kingdom (2) · Argentina (1)
Brendan D Curti, MD (2) · Jonathan L. Finlay, MB, ChB (2) · Lizhi Niu, PhD (2) · Vinay K. Puduvalli, MD (2) · Adi Diab, MD (1) · Afshin Shafie, MD (1) · Agop Y. Bedikian, MD, BS (1) · Agop Y. Bedikian, MD,BS (1) · Ahmad Tarhini, MD, PhD (1) · Al B Benson, MD (1) · Alexander Shoushtari (1) · Alice Lee, MD (1) · Alok Kothari, M.D. (1)
PMID 36648215, PMID 31401903, PMID 37286303, PMID 39116355
2019 (2), N01CM62202 (1), N01CM62204 (1), P01CA168585 (1), P30CA016058 (1), P30CA022453 (1), P50CA174521 (1), R01CA167632 (1), R01CA176659 (1), R21CA186169 (1), R44CA250889 (1), U10CA098543 (1), U10CA180821 (1), U10CA180868 (1), UM1CA081457 (1)